在耐火性青少年异常性关节炎中使用secukinumab治疗
Meghan Corrigan Nelson1,2, Cynthia K Manos1,2
1Emory University School of Medicine, Atlanta, GA, USA.
Journal of investigative medicine high impact case reports
|September 21, 2023
概括
塞库金纽马布在治疗耐火性青少年异常性关节炎 (JIA) 方面表现有前途,包括与肠炎相关的关节炎 (ERA) 和牛皮性关节炎 (PsA). 这种治疗改善了所有患者的MRI检测结果,但对于那些有膜炎病史的人来说,建议谨慎.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 青少年异常性关节炎 (JIA) 是一种常见的儿童慢性疾病,导致显著的发病率.
- 脊椎关节炎亚型,包括牛皮关节炎 (PsA) 和与肠炎相关的关节炎 (ERA),尤其令人担忧.
- 关于secukinumab在JIA中使用的数据有限,特别是耐火病例.
研究的目的:
- 检查secukinumab在患有JIA的儿科患者中的疗效和安全性.
- 评估secukinumab对治疗耐药JIA病例的疾病活性和成像的影响.
主要方法:
- 对10名用secukinumab治疗的JIA患者的回顾性图表审查.
- 数据收集包括疾病活动,人口统计,并发病,药物和实验室结果.
- 磁共振成像 (MRI) 用于评估治疗反应.
主要成果:
- 包括7名ERA,2名PsA和1名多重JIA患者,所有患者都患有高度耐药性疾病 (平均3.8个DMARD失败).
- 100%的患者在接受secukinumab治疗至少3个月后显示MRI改善.
- 一名患者出现了脑膜炎的爆发;没有其他不良事件.
结论:
- 塞库金纽马布是儿童和青少年的潜在有效的治疗选择,与ERA和PsA,即使在耐火病例.
- 在成像和临床评估方面得到的改进支持了它的使用.
- 需要对JIA患者使用sequukinumab进行进一步的研究,这些患者在病史中患有紫外线炎.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Inflammatory Bowel Disease II: Crohn's Disease
279
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
279
Drugs for Treatment of Ulcerative Colitis in IBD
164
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
164


